Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af en intervention for at reducere tiden til behandling for TAVI-patienter (TREAT)

3. november 2026 opdateret af: University Hospital, Rouen

Evaluation d'Une Intervention Pour Reduire le Delai de Traitement Des Patients Traites Par TAVI

Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).

Once a diagnosis has been made and the decision to treat these patients has been taken, the procedure (AVR or TAVI) must be performed rapidly given the poor prognosis of the disease without treatment. Studies have shown that on the waiting list, the probability of death and hospitalisation for heart failure increases with time. This delay could also reduce the effectiveness of TAVI, thus affecting the performance of the healthcare system.

In this study, an intervention combining an e-health component (tool intended for patients, families and health professionals in contact with patients), and an organisational component (for TAVI implanting centres) has been designed. The aim of this study is to evaluate the effectiveness of this intervention.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

828

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Brest, Frankrig
        • Brest University Hospital
      • Rouen, Frankrig
        • CHU de Rouen

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patient over 18 years of age;
  • Aortic stenosis
  • Indication of TAVI
  • Patient affiliated or benefiting from a health insurance scheme
  • Patient having read and understood the information letter and having signed the consent form

Exclusion Criteria:

  • TAVI indication not retained
  • Patient who are not fluent in French and have no one around them to translate,
  • Patient who do not have access to the Internet (at home or in their immediate environment)
  • Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ;
  • Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators
  • History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Control group

The randomized centres in this group will not change their practices.

Eksperimentel: Patient component

The randomized centres in this group will be required to present patients with:

  • A short introductory video, viewed on a tablet during hospitalization for coronary angiography,
  • A paper booklet,
  • A website.

Video, booklet, website

Eksperimentel: Organisational component

The randomized centres in this group will be provided with a list of organisational changes to be implemented to improve patient care times.

Coronarography, CT-scan, anesthesia...

Eksperimentel: Patient and organisational components

The randomized centres in this group will have to implement the two components.

Video, booklet, website

Coronarography, CT-scan, anesthesia...

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate the effectiveness of an intervention combining a patient component and an organisational component
Tidsramme: Month 6

Percentage of patients with a TAVI indication with a time to TAVI procedure of less than 2 months

Month 6

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to care, in days
Tidsramme: Month 6

The time to care is the number of days between the date of the initial consultation during which a TAVI is proposed and the date of the TAVI procedure

Month 6
Mortality rate
Tidsramme: Months 3 and 6

The mortality rate will be measured between the initial consultation during which a TAVI is proposed and the TAVI procedure, and in the three months following the procedure

Months 3 and 6
Patients' health-related quality of life
Tidsramme: Baseline, Months 3 and 6

Patients' health-related quality of life will be measured using the 5-level EQ-5D version (EQ-5D-5L).

Baseline, Months 3 and 6
Patient knowledge of the disease and the TAVI procedure
Tidsramme: Baseline, Month 3

Patients' knowledge of the disease and the TAVI procedure will be measured by their score to an ad hoc questionnaire (0: minimum score - 26: maximum score).

Baseline, Month 3
Medication compliance
Tidsramme: Month 6

Patient medication compliance will be measured using a questionnaire developed by Girerd et al, with a score going from 0 (lowest compliance) to 6 (maximum compliance).

Month 6
Patient satisfaction
Tidsramme: Month 6

Patient satisfaction with the care they received and (for the group receiving the patient component) with the patient component of the intervention will be measured using a 0 to 10 Likert scale

Month 6
Number of visits to the patient section of the website
Tidsramme: Month 6

The number of visits to the website will be assessed through Googleanalytics®

Month 6
Number of visits to the professional section of the website
Tidsramme: Month 6

The number of visits to the website will be assessed through Googleanalytics®

Month 6
Acceptability of the intervention for participating centers
Tidsramme: Month 6

The acceptability of the intervention will be assessed through an ad hoc questionnaire addressed to TAVI centers and peripheral hospitals performing the coronary angiography of the pre-TAVI assessment.

Month 6
Intervention components' dose and fidelity
Tidsramme: Month 6

Number of different activities really performed for each component of the intervention / number of activities planned for each component according to the protocol.

Month 6
Reached populations
Tidsramme: Month 6

Percentage of target individuals who benefit from activities of each component of the intervention

Month 6
Intervention components' adaptation
Tidsramme: Month 6

Number of activities performed which have been modified to adapt them to the local context / total number of activities performed. A description of the adaptations performed will be provided.

Month 6
Incremental cost-effectiveness ratio
Tidsramme: Month 6

The incremental cost-effectiveness ratio will be expressed in cost per quality-adjusted life-year (QALY) gained, derived from the EQ-5D-5L questionnaire

Month 6

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Helene Eltchaninoff, Pr, University Hospital, Rouen

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. oktober 2022

Primær færdiggørelse (Faktiske)

23. oktober 2025

Studieafslutning (Faktiske)

23. oktober 2025

Datoer for studieregistrering

Først indsendt

23. december 2021

Først indsendt, der opfyldte QC-kriterier

11. februar 2022

Først opslået (Faktiske)

14. februar 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. februar 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner